Skip to main content
Menu

Posts tagged with "Drug Prices"

  • Business and Markets

    Shkreli’s Fallout

    A few updates on the Shkreli affair: Biogen’s CEO George Scangos has come out denouncing him and Turing, saying that the price hike is a “perversion of the system”. Good for him: The pricing decision by Martin Shkreli, Turing’s founder and chief executive officer, “dropped down a storm on the whole industry” that drugmak… Read More
  • Drug Prices

    Shkreli, Turing, and PhRMA

    There have been a few developments in the Turing Pharmaceuticals affair. Martin Shkreli, after given several fantastically annoying interviews, finally reversed course and said that the company will lower the price of Daraprim (pyrimethamine). He is not, at the moment, saying what the price will be lowered to: perhaps to merely ten times the previo… Read More
  • Business and Markets

    Martin Shkreli Has One Idea, And It’s a Bad One

    Martin Shkreli may finally have overstepped, and it will be a good thing if he has. Let me back up both those statements. Shkreli, you may recall, was the founder of Retrophin, a company whose business model was to buy up obscure orphan generic drugs (such as Thiola) and immediately raise their price by, say… Read More
  • Drug Prices

    France Elbows Roche Aside on Avastin

    The potential off-label use of Avastin for wet age-related macular degeneration has been a source of many arguments over the last few years. The arguments come because another formulation of the same drug, Lucentis, is what’s actually approved for wet AMD, and it’s significantly more expensive. (The two forms appear to have basically th… Read More
  • Business and Markets

    Biopharma Will Not Be Dull As Long As Martin Shkreli’s Around

    Things really boiled over here last fall when I wrote about Retrophin, their business strategy, and their CEO, Martin Shkreli. That one ended up with a bizarre encounter with Shkreli in real time on Reddit, and to me getting briefly thrown off of that site entirely. Not long afterwards, Shkreli himself was ousted by his… Read More
  • Business and Markets

    GlaxoSmithKline’s New Strategy, Defended

    GlaxoSmithKline’s Moncef Slaoui has an interview in the Philadelphia Inquirer, and he’s responding to critics of the company’s strategy (and to rumors about it): Slaoui suggested some reality for pharma cheerleaders: First, most Americans think drug prices are way too high and sooner or later the bottom will fall out from those fi… Read More
  • Drug Prices

    The Drug Abacus

    How much should drugs cost? That question can be answered in a lot of different ways, and at many levels of economic literacy. But the Wall Street Journal is reporting on a new comparison tool from a group at Sloan-Kettering, the “Drug Abacus“. As you will have already guessed, under many plausible assumptions (such as… Read More
  • Business and Markets

    Piling On Andrew Witty

    To go along with the recent calls for Andrew Witty to step down at GSK, here’s John LaMattina wondering if he’s the right guy for the job as well: . . .the bigger issue with Witty’s stance is the direction that he is taking GSK. His company has a long and proud history of delivering… Read More
  • Business and Markets

    Market Exclusivity Is Sometimes Too Much

    Readers might remember a small company called Catalyst Pharmaceuticals, who have had a business plan that goes something like this: take the known small molecule that’s used for the rare disease Lambert-Eaton Myasthenic Syndrome LEMS, 3,4-diaminopyridine. Rebrand it as “Firdapse”, and do the clinical work needed to get it official… Read More
  • Drug Prices

    More Price Hikes on Obscure Medication

    Get ready for some twists and turns here. I wrote back in September about the business model of Retrophin, a company whose plans (at least for the foreseeable future) were to find small-market drugs, buy them from their obscure producers, and then raise their prices into geosynchronous orbit. That particular story blew up in unforeseen… Read More